Castle Creek Biosciences, Inc. is focused on developing innovative gene therapies aimed at treating genetic diseases, particularly dystrophic epidermolysis bullosa (DEB), a severe skin disorder caused by mutations in the COL7A1 gene. Their lead product, D-Fi (also known as FCX-007), is an autologous cell-based gene therapy designed to address the underlying deficiency of type VII collagen (COL7) in patients with DEB. By utilizing a patient's own dermal fibroblasts, which are genetically modified to produce functional COL7, D-Fi aims to restore the structural integrity of the skin. Clinical studies have shown promising results, with a significant percentage of treated chronic wounds demonstrating substantial healing after administration.

The company's proprietary autologous fibroblast technology underpins their approach to developing personalized therapies for skin and connective tissue disorders. This technology involves collecting small skin biopsies from patients, isolating fibroblast cells, and genetically modifying them using a lentiviral vector to insert a correct copy of the COL7 gene. The modified cells are then injected into affected areas, allowing for localized delivery of the therapeutic protein. This method not only provides a targeted treatment but also allows for the creation of a personalized cell bank for each patient, ensuring long-term therapeutic options. Castle Creek Biosciences is committed to advancing these investigational therapies, which have received various designations from the FDA, including Orphan Drug and Rare Pediatric Disease designations.

United States

Castle Creek Biosciences, Inc., a late-stage cell and gene therapy company, is using two lentiviral platforms to develop and commercialize therapies for genetic diseases.  

Cardiovascular Diseases

Genetic Diseases

Hematologic Diseases

Metabolic Diseases

Musculoskeletal Diseases

Nervous System Diseases

Skin Diseases

Castle Creek Biosciences, Inc.

Recessive dystrophic epidermolysis bullosa

D-Fi (FCX-007)

Biologics

Gene Therapy

Hereditary Tyrosinemia Type 1

LV-FAH

Ehlers-Danlos Syndrome

CCD-003 & CCD-005

Osteogenesis imperfecta

CCB-001

Phenylketonuria

LV-PAH

Pennsylvania

Cell Therapies

Lentiviral Vector (LVV)

Small Molecule Pharmaceuticals

Therapeutic

Castle Creek Biosciences, Inc.

Company Details